KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Tax Provisions (2016 - 2025)

Emergent BioSolutions' Tax Provisions history spans 15 years, with the latest figure at $3.9 million for Q4 2025.

  • For Q4 2025, Tax Provisions rose 5.41% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $30.2 million, down 36.69%, while the annual FY2025 figure was $30.2 million, 36.69% down from the prior year.
  • Tax Provisions reached $3.9 million in Q4 2025 per EBS's latest filing, down from $6.4 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $78.4 million in Q4 2021 to a low of -$26.4 million in Q2 2022.
  • Average Tax Provisions over 5 years is $9.5 million, with a median of $4.8 million recorded in 2022.
  • Peak YoY movement for Tax Provisions: tumbled 1115.38% in 2022, then surged 25700.0% in 2023.
  • A 5-year view of Tax Provisions shows it stood at $78.4 million in 2021, then tumbled by 92.86% to $5.6 million in 2022, then plummeted by 189.29% to -$5.0 million in 2023, then surged by 174.0% to $3.7 million in 2024, then increased by 5.41% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Tax Provisions are $3.9 million (Q4 2025), $6.4 million (Q3 2025), and -$4.8 million (Q2 2025).